Menu Search
Equities

Aurinia Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IKAP:MUN

Aurinia Pharmaceuticals Inc

Actions
  • Price (EUR)12.18
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change+55.44%
  • Beta1.5421
Data delayed at least 15 minutes, as of Feb 11 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

  • Revenue in USD (TTM)265.81m
  • Net income in USD77.84m
  • Incorporated2009
  • Employees300.00
  • Location
    Aurinia Pharmaceuticals Inc#140, 14315 - 118 AVENUEEDMONTON T5L 4S6CanadaCAN
  • Phone+1 (250) 744-2487
  • Fax+1 (250) 708-4345
  • Websitehttps://www.auriniapharma.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.